Carrie L. Griffiths
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Carrie L. Griffiths has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Desiree E. Kosmisky
Atrium Health Virtual Critical Care Wingate North Carolina USA
3 shared publications - Sonia S. Everhart
Atrium Health Virtual Critical Care Wingate North Carolina USA
3 shared publications - Angela Pegram
Wingate University School of Pharmacy
1 shared publication Charlene P. Knight
Atrium Health Lincoln Lincolnton North Carolina USA
1 shared publication- Danielle Tully
Wingate University School of Pharmacy, Levine College of Health Sciences, Wingate, NC, USA
1 shared publication Karen S. Marshall
Atrium Health Lincoln Lincolnton North Carolina USA
1 shared publication
Latest Publications
- Open Access
- 10 July 2023
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (8) , 900-908
Characterization of tele‐pharmacy interventions performed via an expanded tele‐critical care pharmacist protocol
- 10 July 2023
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (8) , 900-908
Open AccessCharacterization of tele‐pharmacy interventions performed via an expanded tele‐critical care pharmacist protocol
- Open Access
- 15 June 2023
- Published by ISTES Organization in International Journal on Engineering, Science and Technology
- Vol. 4 (4) , 301-307
Impact of Low-Fidelity Simulation Based Learning in a Cardiovascular Pharmacotherapy Module
To determine the impact of low-fidelity simulation (LFS) on the comprehension of 5 major cardiovascular diseases in a pharmacotherapy module. Study population included pharmacy students enrolled in the cardiovascular pharmacotherapy from 2020-2022. Baseline knowledge was obtained by comparing practice quiz answers to corresponding exam questions. Near the course end, answers from the LFS patient case involving the 5 diseases were compared to corresponding final exam questions. The percentage correct was compared to see if LFS has more impact than practice quizzes on exam grades. All groups showed approximately the same percentage correct exam questions from practice quizzes. LFS was superior to practice quizzes in percentage correct on exam questions in 4/5 disease states for the class enrolled in 2021. However, opposite results were shown for the class enrolled in 2022, with practice quizzes showing a larger improvement over the LFS activity on exam questions in all 5 disease states. Although data was mixed, the use of LFS is a viable addition to classroom learning in complicated pharmacotherapy courses. There is a paucity of literature published to date in the health sciences literature on the use of LFS; therefore, this adds to the body of evidence to support learning via simulation.
- 15 June 2023
- Published by ISTES Organization in International Journal on Engineering, Science and Technology
- Vol. 4 (4) , 301-307
Open AccessImpact of Low-Fidelity Simulation Based Learning in a Cardiovascular Pharmacotherapy Module
To determine the impact of low-fidelity simulation (LFS) on the comprehension of 5 major cardiovascular diseases in a pharmacotherapy module. Study population included pharmacy students enrolled in the cardiovascular pharmacotherapy from 2020-2022. Baseline knowledge was obtained by comparing practice quiz answers to corresponding exam questions. Near the course end, answers from the LFS patient case involving the 5 diseases were compared to corresponding final exam questions. The percentage correct was compared to see if LFS has more impact than practice quizzes on exam grades. All groups showed approximately the same percentage correct exam questions from practice quizzes. LFS was superior to practice quizzes in percentage correct on exam questions in 4/5 disease states for the class enrolled in 2021. However, opposite results were shown for the class enrolled in 2022, with practice quizzes showing a larger improvement over the LFS activity on exam questions in all 5 disease states. Although data was mixed, the use of LFS is a viable addition to classroom learning in complicated pharmacotherapy courses. There is a paucity of literature published to date in the health sciences literature on the use of LFS; therefore, this adds to the body of evidence to support learning via simulation.
- Open Access
- 1 August 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 4 (8) , 988-993
Impact of first and second shift tele-critical care pharmacy services and virtual rounds on interventions at Atrium Health Lincoln
- 1 August 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 4 (8) , 988-993
Open AccessImpact of first and second shift tele-critical care pharmacy services and virtual rounds on interventions at Atrium Health Lincoln
- Open Access
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Vaccines and Immunotherapy
- Vol. 9
Dengvaxia: the world’s first vaccine for prevention of secondary dengue
The objective of this manuscript was to review and evaluate the efficacy and safety data of Dengvaxia for the treatment of severe secondary dengue infection. Dengvaxia is the brand name for chimeric yellow fever-dengue-tetravalent dengue vaccine (CYD-TDV). A literature search through PubMed was conducted using the keywords ‘dengue vaccine’, ‘Dengvaxia’, ‘efficacy’ or ‘safety’. Trials were selected if they appropriately assessed vaccine efficacy or were related to the vaccine approval process for CYD-TDV. Findings from this review underline the evolution of vaccine efficacy against seroprevalence, serotypes, and various ages. There are currently no preventive measures or antiviral treatments for dengue; CYD-TDV is the first vaccine to receive US Food and Drug Administration approval. Protective responses seen with the complete administration of CYD-TDV can become a standardized tool as part of a world vaccination program.
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Vaccines and Immunotherapy
- Vol. 9
Open AccessDengvaxia: the world’s first vaccine for prevention of secondary dengue
The objective of this manuscript was to review and evaluate the efficacy and safety data of Dengvaxia for the treatment of severe secondary dengue infection. Dengvaxia is the brand name for chimeric yellow fever-dengue-tetravalent dengue vaccine (CYD-TDV). A literature search through PubMed was conducted using the keywords ‘dengue vaccine’, ‘Dengvaxia’, ‘efficacy’ or ‘safety’. Trials were selected if they appropriately assessed vaccine efficacy or were related to the vaccine approval process for CYD-TDV. Findings from this review underline the evolution of vaccine efficacy against seroprevalence, serotypes, and various ages. There are currently no preventive measures or antiviral treatments for dengue; CYD-TDV is the first vaccine to receive US Food and Drug Administration approval. Protective responses seen with the complete administration of CYD-TDV can become a standardized tool as part of a world vaccination program.
- 30 March 2020
- Published by SAGE Publications in Journal of Telemedicine and Telecare
- Vol. 28 (1) , 77-80
Characterization of dayshift tele-ICU pharmacist activities
Background: Critical care services have expanded over the last decade to include tele-ICU. In 2015, Atrium Health’s pharmacy services began covering tele-ICU patients from 3–11 PM. In 2017, dayshift tele-ICU pharmacy services were added on Monday, Wednesday and Friday from 8 AM to 12 PM. Cutting-edge technology and software integration allow alerts to be generated in areas of abnormal glucose, electrolyte and lactate levels. This analysis was conducted to describe the interventions recommended during dayshift hours. Methods: Data collected from 1 August 2017 to 30 June 2018, the first 11 months of dayshift pharmacist coverage, include number of charts reviewed per shift, interventions and specific types logged, if the intervention was tied to an alert and if it was accepted or rejected. Interventions can originate from alerts or from proactive assessment by the pharmacist. Descriptive statistics were reported. Results: On average, 41 charts were reviewed per shift. Over an 11-month period, 1024 interventions were made for 634 patient chart reviews. Some 89% of all interventions were accepted or accepted with modifications. Of the total interventions, 37 (3.6%) were adverse drug events avoided and 658 (64.4%) were interventions unrelated to alert data. Medication management accounted for 44.3% of all interventions. Discussion: Proactive assessment rather than alert review resulted in the majority of interventions, demonstrating that reviewing every ICU patient is vital for improving patient care. Determining optimal avenues for intervention delivery and integration with the bedside multidisciplinary teams remains one of the biggest challenges. Dayshift innovations included weekly virtual rounds and providing drug information for the bedside teams.
- 30 March 2020
- Published by SAGE Publications in Journal of Telemedicine and Telecare
- Vol. 28 (1) , 77-80
Characterization of dayshift tele-ICU pharmacist activities
Background: Critical care services have expanded over the last decade to include tele-ICU. In 2015, Atrium Health’s pharmacy services began covering tele-ICU patients from 3–11 PM. In 2017, dayshift tele-ICU pharmacy services were added on Monday, Wednesday and Friday from 8 AM to 12 PM. Cutting-edge technology and software integration allow alerts to be generated in areas of abnormal glucose, electrolyte and lactate levels. This analysis was conducted to describe the interventions recommended during dayshift hours. Methods: Data collected from 1 August 2017 to 30 June 2018, the first 11 months of dayshift pharmacist coverage, include number of charts reviewed per shift, interventions and specific types logged, if the intervention was tied to an alert and if it was accepted or rejected. Interventions can originate from alerts or from proactive assessment by the pharmacist. Descriptive statistics were reported. Results: On average, 41 charts were reviewed per shift. Over an 11-month period, 1024 interventions were made for 634 patient chart reviews. Some 89% of all interventions were accepted or accepted with modifications. Of the total interventions, 37 (3.6%) were adverse drug events avoided and 658 (64.4%) were interventions unrelated to alert data. Medication management accounted for 44.3% of all interventions. Discussion: Proactive assessment rather than alert review resulted in the majority of interventions, demonstrating that reviewing every ICU patient is vital for improving patient care. Determining optimal avenues for intervention delivery and integration with the bedside multidisciplinary teams remains one of the biggest challenges. Dayshift innovations included weekly virtual rounds and providing drug information for the bedside teams.
- 1 October 2014
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 49 (10) , 950-955
Assessment of the Intensive Care Unit Treatment of Pneumonia at a Veterans Affairs Facility
Introduction: Pneumonia is a common cause of morbidity and mortality in the critically ill. Clinicians use a range of duration for antibiotic treatment from 7 to 14 days or longer. Failure to de-escalate antimicrobial therapy in a timely manner may lead to increased antimicrobial resistance, increased risk of side effects, and increased cost. Objective: To investigate potential methods to improve treatment of pneumonia for patients in 4 intensive care units (ICUs). Methods: A retrospective descriptive chart review was conducted at the Veterans Affairs North Texas Health Care System (VANTHCS). Veterans aged 18 to 90 years admitted to the ICU with a diagnosis of pneumonia were included. Descriptive statistics were used to interpret the data. Current management was reviewed to identify markers such as length of antibiotic therapy, ICU length of stay, and inpatient mortality. Secondary objectives included appropriateness and accuracy of the empiric regimen. Results: Of the 1,854 Veterans admitted, 107 met inclusion criteria. Antibiotic choices for positive cultures were appropriate in 45 out of 46 (98%) patients, with an average length of therapy of 8.6 ± 6.3 days. De-escalation of antibiotics based on sensitivity data occurred in 73% of positive cultures. Conclusions: Pneumonia in the VANTHCS ICUs is initially treated with empiric antibiotics. Empiric antibiotic therapy for pneumonia was appropriate and accurate over this time period. Opportunities exist for de-escalation in patients with or without positive cultures. The procalcitonin assay is now being utilized at VANTHCS to optimize patient care.
- 1 October 2014
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 49 (10) , 950-955
Assessment of the Intensive Care Unit Treatment of Pneumonia at a Veterans Affairs Facility
Introduction: Pneumonia is a common cause of morbidity and mortality in the critically ill. Clinicians use a range of duration for antibiotic treatment from 7 to 14 days or longer. Failure to de-escalate antimicrobial therapy in a timely manner may lead to increased antimicrobial resistance, increased risk of side effects, and increased cost. Objective: To investigate potential methods to improve treatment of pneumonia for patients in 4 intensive care units (ICUs). Methods: A retrospective descriptive chart review was conducted at the Veterans Affairs North Texas Health Care System (VANTHCS). Veterans aged 18 to 90 years admitted to the ICU with a diagnosis of pneumonia were included. Descriptive statistics were used to interpret the data. Current management was reviewed to identify markers such as length of antibiotic therapy, ICU length of stay, and inpatient mortality. Secondary objectives included appropriateness and accuracy of the empiric regimen. Results: Of the 1,854 Veterans admitted, 107 met inclusion criteria. Antibiotic choices for positive cultures were appropriate in 45 out of 46 (98%) patients, with an average length of therapy of 8.6 ± 6.3 days. De-escalation of antibiotics based on sensitivity data occurred in 73% of positive cultures. Conclusions: Pneumonia in the VANTHCS ICUs is initially treated with empiric antibiotics. Empiric antibiotic therapy for pneumonia was appropriate and accurate over this time period. Opportunities exist for de-escalation in patients with or without positive cultures. The procalcitonin assay is now being utilized at VANTHCS to optimize patient care.